SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced that a study published online in Clinical Cancer Research showed that the PAM50 assay, on which the company’s Prosigna™ Breast Cancer Prognostic Gene Signature Assay is based, accurately assessed the risk of late distant recurrence in postmenopausal women with estrogen receptor-positive (ER+) early-stage breast cancer.
Help employers find you! Check out all the jobs and post your resume.
